Pliant Therapeutics (PLRX) Cash from Investing Activities (2019 - 2026)

Pliant Therapeutics (PLRX) has reported Cash from Investing Activities for 8 consecutive years, with -$4.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 105.93% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at $61.1 million (down 59.26% YoY), while the FY2025 annual figure was $134.3 million, down 4.31% from the prior year.
• Cash from Investing Activities declined to -$4.1 million in Q1 2026 per PLRX's latest filing, from $1.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $69.1 million in Q1 2025 and bottomed at -$178.3 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged -$393294.1 across 5 years, with a median of $20.0 million in 2022.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 11478.71% — and 2025, when it soared 231.59%.
• Pliant Therapeutics' Cash from Investing Activities stood at $20.0 million in 2022, then soared by 59.43% to $31.9 million in 2023, then grew by 22.59% to $39.1 million in 2024, then slumped by 95.48% to $1.8 million in 2025, then tumbled by 331.9% to -$4.1 million in 2026.
• Business Quant data shows PLRX's Cash from Investing Activities at -$4.1 million in Q1 2026, $1.8 million in Q4 2025, and $27.9 million in Q3 2025.